{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:52:04Z","timestamp":1790373124722,"version":"4.1.0"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02740","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T06:19:13Z","timestamp":1543817953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":76,"title":["CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success"],"prefix":"10.3389","volume":"9","author":[{"given":"Kristen B.","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina C.","family":"Boesteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Joseph","family":"Melenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"DeGaramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B9","unstructured":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma238997 GoffSL DudleyME CitrinDE SomervilleRP WunderlichJR DanforthDN 10.1200\/JCO.2016.66.722027217459J Clin Oncol.342016"},{"key":"B10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","article-title":"Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions","volume":"20","author":"Lu","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1172\/JCI82416","article-title":"Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes","volume":"125","author":"Cohen","year":"2015","journal-title":"J Clin Invest."},{"key":"B14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","article-title":"Immunogenicity of somatic mutations in human gastrointestinal cancers","volume":"350","author":"Tran","year":"2015","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovic","year":"2017","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0065-2776(08)60561-1","article-title":"Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors","volume":"68","author":"Brocker","year":"1998","journal-title":"Adv Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-immunol-032713-120136","article-title":"Adoptive immunotherapy for cancer or viruses","volume":"32","author":"Maus","year":"2014","journal-title":"Annu Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S0301-472X(01)00693-2","article-title":"Protein-protein interactions in hematology and phage display","volume":"29","author":"Mullaney","year":"2001","journal-title":"Exp Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1002\/jcp.25419","article-title":"How chimeric antigen receptor design affects adoptive T cell therapy","volume":"231","author":"Gacerez","year":"2016","journal-title":"J Cell Physiol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","author":"Lamers","year":"2006","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","article-title":"Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells","volume":"159","author":"Levine","year":"1997","journal-title":"J Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest."},{"key":"B37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11899-017-0373-2","article-title":"CARs in the lead against multiple myeloma","volume":"12","author":"Ormhoj","year":"2017","journal-title":"Curr Hematol Malig Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"275ra222","DOI":"10.1126\/scitranslmed.aaa4963","article-title":"Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Sci Transl Med."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front Immunol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao2731","article-title":"Constitutive and TNFalpha-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: implications for CAR-T cell therapy","author":"Pellegatta","year":"2018","journal-title":"Sci Transl Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"99573","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B56","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J Clin Invest."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2002-07-2015","article-title":"Telomerase levels control the lifespan of human T lymphocytes","volume":"102","author":"Roth","year":"2003","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1084\/jem.20021288","article-title":"Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production","volume":"198","author":"Topp","year":"2003","journal-title":"J Exp Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex vivo culture improves the anti-leukemic activity of Chimeric Antigen Receptor (CAR)-T cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"95103","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3389\/fimmu.2017.01221","article-title":"PI3Kdelta inhibition enhances the antitumor fitness of adoptively transferred CD8(+) T cells","volume":"8","author":"Bowers","year":"2017","journal-title":"Front Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/1074-7613(95)90141-8","article-title":"The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15","volume":"2","author":"Lin","year":"1995","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1084\/jem.20020066","article-title":"Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells","volume":"195","author":"Tan","year":"2002","journal-title":"J Exp Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.4049\/jimmunol.170.10.5018","article-title":"IL-15 promotes the survival of naive and memory phenotype CD8+ T cells","volume":"170","author":"Berard","year":"2003","journal-title":"J Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2567.2006.02429.x","article-title":"Prolonged exposure of naive CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length","volume":"119","author":"Wallace","year":"2006","journal-title":"Immunology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2008-05-156059","article-title":"IL-7 and IL-15 allow the generation of suicide gene\u2013modified alloreactive self-renewing central memory human T lymphocytes","volume":"113","author":"Kaneko","year":"2009","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.stem.2010.06.004","article-title":"Reprogramming of T cells from human peripheral blood","volume":"7","author":"Loh","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1172\/JCI86437","article-title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J Clin Invest."},{"key":"B78","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature24633","article-title":"Origin and differentiation of human memory CD8 T cells after vaccination","volume":"552","author":"Akondy","year":"2017","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature25144","article-title":"Effector CD8 T cells dedifferentiate into long-lived memory cells","volume":"552","author":"Youngblood","year":"2017","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.aah6499","article-title":"The epigenetic control of stemness in CD8(+) T cell fate commitment","volume":"359","author":"Pace","year":"2018","journal-title":"Science"},{"key":"B82","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1208\/s12248-010-9181-5","article-title":"Pancreatic cancer: pathobiology, treatment options, and drug delivery","volume":"12","author":"Li","year":"2010","journal-title":"AAPS J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fonc.2015.00245","article-title":"The extracellular matrix in epithelial ovarian cancer-a piece of a puzzle","volume":"5","author":"Cho","year":"2015","journal-title":"Front Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10555-016-9650-0","article-title":"From transformation to metastasis: deconstructing the extracellular matrix in breast cancer","volume":"35","author":"Kaushik","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/hum.2015.054","article-title":"CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma","volume":"26","author":"Enblad","year":"2015","journal-title":"Hum Gene Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/mto.2016.6","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B89","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B90","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med."},{"key":"B91","first-page":"2497","article-title":"Role of extracellular matrix assembly in interstitial transport in solid tumors","volume":"60","author":"Netti","year":"2000","journal-title":"Cancer Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/sj.bjc.6602626","article-title":"Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts","volume":"93","author":"Eikenes","year":"2005","journal-title":"Br J Cancer"},{"key":"B93","first-page":"265","article-title":"Increased nanoparticle penetration in collagenase-treated multicellular spheroids","volume":"2","author":"Goodman","year":"2007","journal-title":"Int J Nanomed."},{"key":"B94","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-15-1032","article-title":"IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma","volume":"6","author":"Long","year":"2016","journal-title":"Cancer Discov."},{"key":"B96","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B97","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"B99","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ccell.2015.11.002","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"28","author":"Ozdemir","year":"2015","journal-title":"Cancer Cell"},{"key":"B100","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett."},{"key":"B101","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/icb.2016.128","article-title":"CAR T-cell therapy of solid tumors","volume":"95","author":"Yong","year":"2017","journal-title":"Immunol Cell Biol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/eji.200424938","article-title":"The alpha v beta 3 integrin as a tumor homing ligand for lymphocytes","volume":"34","author":"Legler","year":"2004","journal-title":"Eur J Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1002\/ijc.28269","article-title":"Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery","volume":"133","author":"Fu","year":"2013","journal-title":"Int J Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.12.003.","article-title":"Macrophages: key orchestrators of a tumor microenvironment defined by therapeutic resistance","author":"Long","year":"2017","journal-title":"Mol Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov."},{"key":"B116","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.06.010","article-title":"Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps","volume":"166","author":"Beatty","year":"2016","journal-title":"Pharmacol Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol Immunother."},{"key":"B118","doi-asserted-by":"publisher","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","article-title":"Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species","volume":"172","author":"Kusmartsev","year":"2004","journal-title":"J Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed catalase protects chimeric antigen receptor-redirected t cells as well as bystander cells from oxidative stress-induced loss of antitumor activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-11-1156","article-title":"Targeting regulatory T cells in cancer","volume":"71","author":"Byrne","year":"2011","journal-title":"Cancer Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10555-018-9740-2","article-title":"Role of prostaglandins in tumor microenvironment","volume":"37","author":"Kobayashi","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"B126","doi-asserted-by":"publisher","first-page":"27571","DOI":"10.1074\/jbc.M110.127100","article-title":"Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells","volume":"285","author":"Mandapathil","year":"2010","journal-title":"J Biol Chem."},{"key":"B127","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","article-title":"Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization","volume":"4","author":"Newick","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","article-title":"Metabolic heterogeneity in human lung tumors","volume":"164","author":"Hensley","year":"2016","journal-title":"Cell"},{"key":"B129","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","article-title":"Metabolic instruction of immunity","volume":"169","author":"Buck","year":"2017","journal-title":"Cell"},{"key":"B130","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.4049\/jimmunol.0803510","article-title":"Anergic T cells are metabolically anergic","volume":"183","author":"Zheng","year":"2009","journal-title":"J Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev-immunol-032712-095956","article-title":"Metabolic regulation of T lymphocytes","volume":"31","author":"MacIver","year":"2013","journal-title":"Annu Rev Immunol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ni.2714","article-title":"Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen","volume":"14","author":"Doedens","year":"2013","journal-title":"Nat Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature20165","article-title":"S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate","volume":"540","author":"Tyrakis","year":"2016","journal-title":"Nature"},{"key":"B135","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","article-title":"Enhancing CD8(+) T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy","volume":"32","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"key":"B136","doi-asserted-by":"publisher","first-page":"93411","DOI":"10.1172\/jci.insight.93411","article-title":"Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma","volume":"2","author":"Siska","year":"2017","journal-title":"JCI Insight"},{"key":"B137","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","article-title":"Hypoxia, Hypoxia-inducible transcription factors, and renal cancer","volume":"69","author":"Schodel","year":"2016","journal-title":"Eur Urol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2013a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2009.03.018","article-title":"Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells","volume":"15","author":"Li","year":"2009","journal-title":"Cancer Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"key":"B143","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S1471-4906(03)00141-8","article-title":"Regulation of quiescence in lymphocytes","volume":"24","author":"Yusuf","year":"2003","journal-title":"Trends Immunol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.it.2014.12.004","article-title":"Targeting T cell metabolism for therapy","volume":"36","author":"O'Sullivan","year":"2015","journal-title":"Trends Immunol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van","year":"2012","journal-title":"Immunity"},{"key":"B146","doi-asserted-by":"publisher","first-page":"14336","DOI":"10.1073\/pnas.1221740110","article-title":"CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability","volume":"110","author":"van","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander","year":"2009","journal-title":"Science"},{"key":"B148","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.immuni.2014.04.007","article-title":"Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation","volume":"40","author":"Nakaya","year":"2014","journal-title":"Immunity"},{"key":"B149","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/0008-5472.CAN-14-2277","article-title":"Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics","volume":"75","author":"Crompton","year":"2015","journal-title":"Cancer Res."},{"key":"B150","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ebiom.2016.01.019","article-title":"Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells","volume":"4","author":"Scholz","year":"2016","journal-title":"EBioMedicine"},{"key":"B151","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","article-title":"Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy","volume":"23","author":"Sukumar","year":"2016","journal-title":"Cell Metab."},{"key":"B152","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2017.03.011","article-title":"Metabolic reprograming of anti-tumor immunity","volume":"46","author":"Sukumar","year":"2017","journal-title":"Curr Opin Immunol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B154","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fimmu.2017.00267","article-title":"Engineering chimeric antigen receptor T-cells for racing in solid tumors: don't forget the fuel","volume":"8","author":"Irving","year":"2017","journal-title":"Front Immunol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest."},{"key":"B156","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fimmu.2013.00417","article-title":"Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go","volume":"4","author":"Vasaturo","year":"2013","journal-title":"Front Immunol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B158","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B159","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"B160","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B161","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T19:04:41Z","timestamp":1694459081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":161,"alternative-id":["10.3389\/fimmu.2018.02740"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02740","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"article-number":"2740"}}